Applied DNA Sciences Approved for S&P Listing; Company Also Engages The Del Mar Consulting Group, Inc.

Business Editors

LOS ANGELES--(BUSINESS WIRE)--Jan. 14, 2003

Applied DNA Sciences, Inc. (OTCBB:APDN), a provider of DNA-embedded biotechnology solutions that protect corporate and government intellectual property from counterfeiting and fraud, today announced that the Standard & Poor's Editorial Board has approved the company for inclusion in the Standard & Poor's Standard Corporation Records. A full description will be published in the Daily News Section of Standard Corporation Records.

Applied DNA Sciences Inc.'s listing in Standard Corporation Records provides universal dissemination of company information and heightens awareness of Applied DNA Sciences, Inc. (ADNAS) to the financial community. Standard Corporation Records is a recognized securities manual for "Blue Sky/manual exemption" trading in approximately 35 states under the Blue Sky Laws.

Separately, the company announced that it has engaged The Del Mar Consulting Group, Inc., ("DCG") based in Del Mar, CA to represent the company in its investor relations and corporate communications activities. DCG (www.delmarconsulting.com) is a leader in assisting and advising micro-cap and small-cap public companies in the areas of investor & media relations, strategic management planning, capital formation, and mergers & acquisitions.

About Applied DNA Sciences, Inc. (ADNAS)

Applied DNA Sciences, Inc. (www.adnas.com) provides proprietary DNA-embedded biotechnology solutions that confirm authenticity and protect corporate and government agencies from counterfeiting, fraud, piracy, product diversion, and unauthorized intrusion. ADNAS has an exclusive licensing and partnership agreement covering North America and Europe with Biowell Technology, Inc. (http://www.biowell.com.tw/eng/home.htm) of Taiwan. The company provides sales, marketing, and sub-licensing of the DNA products, which are accompanied by monitoring and enforcement support to identify, deter, and apprehend global counterfeiting organizations.

ADNAS' patented technology addresses the more than $350 billion of counterfeit products sold globally each year. Corporations spend approximately $6 billion annually on anti-counterfeit and anti-fraud solutions. DNA tagging provides an extremely high counterfeit barrier, because the unique DNA sequence that identifies a tagged object is virtually impossible for a counterfeiter to replicate. Industries benefiting from ADNAS solutions include: corporations, federal government, information technology, security and surveillance, entertainment, the arts, cosmetics, pharmaceuticals, agriculture, biometrics, and vertical retail markets.

The company is headquartered at 9255 W. Sunset Blvd., Los Angeles, CA 90069; Tel: [phone]DNA (1362); Fax: [phone].

The statements made by Applied DNA Sciences, Inc. (the Company) may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe The Company's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA Sciences, Inc. Actual results could differ materially from those projected due to changes in interest rates, market competition, changes in the local and national economies, and various other factors. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.